Precision Medicine:
Harnessing Automation & AI for Transformative Oncology Care.

Introduction

Welcome to the intersection of the latest technologies and precision medicine. We know that the future of cancer treatment will be smarter, faster and more precise to the specific person and case. But do we know how?

This whitepaper gives a big picture overview of precision-medicine efforts in cancer research, and how the latest technologies contribute to the development of more personalized treatments. Our goal: a clear view of how precision medicine, with a little help from automation and AI, can tackle the biggest challenges in cancer treatment and make it significantly more personalized and effective.

Challenges with cancer research

Three major challenges impact patient outcomes and the overall efficiency of healthcare systems in cancer research and treatment.

High costs. Developing and delivering cancer therapies is not cheap and the costs can be astronomical. Long-term cancer care, with its diagnostics, treatments and follow-ups, risks seriously straining resources for both patients and healthcare systems.

Inefficiencies. Traditional cancer treatments often take a one-size-fits-all approach. Different patients respond in drastically different ways to the same treatment, which leads to longer, less predictable treatment times and higher costs.

Lack of personalized treatments. Many cancer treatments fail to consider the unique genetic and molecular profiles of individual tumours and patients. This can result in less effective treatments, and unwanted side effects are common in the methods available today.

That makes precision medicine a prime area of development: it reduces healthcare costs by optimizing resources and cutting trial-and-error, advances cancer research by improving our understanding of cancer mechanisms, and improves patient outcomes through treatment strategies that are more effective and less debilitating. Precision medicine is about treating the person and not just the disease.

Precision medicine: a background

Precision medicine, also known as personalized medicine, tailors medical treatment to the individual characteristics of each patient. The concept has been around for decades, from the discovery of blood groups in the 1900s and DNA structure in the 1950s to the genetic markers of the 1970s and 1990s. It gained significant momentum with the completion of the Human Genome Project in 2003, which mapped the entire human genome and provided unprecedented insight into genetic variation. The US NIH Precision Medicine Initiative (2011) and the White House Precision Medicine Initiative (2015) followed, and the 2020s added omics technologies, machine learning for predictive models, and liquid biopsies as minimally invasive diagnostic and monitoring tools.

Today precision medicine is particularly prominent in oncology, where genetic profiling of tumours allows for tailored treatment strategies: targeted therapies against specific mutations, immunotherapy guided by genetic markers, pharmacogenomics to predict drug response, and companion diagnostics that identify who will benefit from a given treatment. Challenges remain around data integration and security, standardization of genetic testing and equitable access. Enabling technologies help with this: imaging, genomics and bioinformatics, automation, AI and machine learning, and quantum computing.

Precision medicine and oncology

Precision medicine has emerged as a transformative approach in oncology, fundamentally altering how cancer is diagnosed, treated and managed. Its significance lies in several key areas: advanced diagnostics and early detection through next-generation sequencing and liquid biopsies; personalized treatment plans tailored to the genetic profile of the individual tumour; targeted therapies focused on the specific mutations driving cancer growth; and improved clinical outcomes, with higher response rates, longer survival times and better quality of life.

The published case studies make this concrete. Patients with non-small cell lung cancer carrying an EGFR mutation showed tumour regression under the EGFR inhibitor gefitinib. HER2-positive breast cancer patients benefited from trastuzumab, which significantly improves survival rates when combined with chemotherapy. In BRAF-mutant melanoma, vemurafenib has shown remarkable efficacy. Imatinib transformed chronic myeloid leukemia from a fatal disease into a manageable chronic condition, and CAR-T cell therapy has led to unprecedented remission rates in relapsed or refractory acute lymphoblastic leukemia.

How AI helps with personalized treatments

AI can analyze genomic, proteomic and clinical information to uncover patterns and predict effective molecules, reducing the time and cost of trial-and-error in drug discovery. Automation accelerates laboratory workflows and experimental procedures, while AI supports experiment design and the interpretation of complex biological data.

Precision medicine relies on vast amounts of data from genomic sequencing, clinical records and patient histories. Automated tools make that data easier to gather, keep and work with, and AI helps identify the trends inside it. AI-powered diagnostic tools analyze imaging and pathological data, detecting cancer cells and genetic mutations more accurately than traditional methods. Predictive analytics spot patterns across large datasets to show how disease might progress, and AI-driven tools generate personalized treatment recommendations from a patient's unique genetic profile.

Intelligent integration of technologies

Precision medicine, automation and AI together deliver personalized cancer treatments more efficiently. The whitepaper gathers examples across the field: decision-support systems whose treatment recommendations matched expert oncologists in 93% of more than 1,000 cases; deep-learning models trained on thousands of retinal scans, now being adapted to pathology slides and radiology images; platforms that integrate genomic sequencing, clinical data and imaging to return comprehensive genomic profiles and treatment options within days; and algorithms trained on over 100,000 chest X-rays performing comparably to expert radiologists.

Multiomics is where this pays off for targeted treatments. Combining genomics, transcriptomics and proteomics revealed the biomarkers behind osimertinib for EGFR-mutated NSCLC. Multi-layered tumour data has exposed the pathways implicated in drug resistance. Multiomics has enabled the repurposing of existing drugs into new indications, in breast cancer and in advanced melanoma. Roche applied multiomics to integrate genomic, proteomic and metabolomic profiles from patient samples, identifying molecular signatures that predict individual response and improving response rates in metastatic colorectal cancer.

Key insights

Critical role in oncology. Precision medicine allows for personalized treatment plans that consider individual genetic and molecular profiles, leading to more effective and less harmful cancer therapies.

Integration of automation and AI. These technologies streamline experiment and data management, improve predictive analytics and enable personalized treatment plans. They are crucial in handling the complexity and volume of data that effective precision medicine requires.

Real-world impact. Case studies from leading pharmaceutical companies and research groups show how multiomics approaches, enabled by automation and AI, have led to significant advances in drug discovery, repurposing and personalized treatment plans.

Future prospects. The integration of the right technologies leads to greater innovation in oncology, from more accurate predictive models to faster and more cost-effective drug development.